Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.28% | -3.57% | -11.23% | -8.49% | -19.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.92% | -1.62% | -22.93% | 24.18% | 19.10% |
| Operating Income | -6.92% | 1.62% | 22.93% | -24.18% | -19.10% |
| Income Before Tax | -17.32% | 3.01% | 29.58% | 24.53% | -34.35% |
| Income Tax Expenses | 79.17% | 123.53% | -152.27% | 1,131.71% | -158.54% |
| Earnings from Continuing Operations | -17.45% | 2.77% | 29.89% | 22.56% | -33.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.45% | 2.77% | 29.89% | 22.56% | -33.72% |
| EBIT | -6.92% | 1.62% | 22.93% | -24.18% | -19.10% |
| EBITDA | -7.42% | 1.29% | 24.80% | -23.39% | -18.15% |
| EPS Basic | -16.40% | 3.86% | 30.84% | 23.84% | -31.23% |
| Normalized Basic EPS | -16.27% | 4.08% | 30.54% | -5.42% | -31.82% |
| EPS Diluted | -16.40% | 3.86% | 30.84% | 23.84% | -31.23% |
| Normalized Diluted EPS | -16.27% | 4.08% | 30.54% | -5.42% | -31.82% |
| Average Basic Shares Outstanding | 0.90% | 1.14% | 1.38% | 1.69% | 1.92% |
| Average Diluted Shares Outstanding | 0.90% | 1.14% | 1.38% | 1.69% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
